Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project
- PMID: 39951177
- PMCID: PMC12181551
- DOI: 10.1007/s11357-024-01484-7
Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project
Abstract
Companion dogs are a powerful model for aging research given their morphologic and genetic variability, risk for age-related disease, and habitation of the human environment. In addition, the shorter life expectancy of dogs compared to human beings provides a unique opportunity for an accelerated timeline to test interventions that might extend healthy lifespan. The Test of Rapamycin In Aging Dogs (TRIAD) randomized clinical trial is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test the ability of rapamycin to prolong lifespan and improve several healthspan metrics in healthy, middle-aged dogs recruited from Dog Aging Project participants. Here, we describe the rationale, design, and goals of the TRIAD randomized clinical trial, the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species.
Keywords: Canine; Healthspan; Life span; Lifespan; Longevity; Rapamycin.
© 2025. The Author(s), under exclusive licence to American Aging Association.
Conflict of interest statement
Declarations. IACUC approval declaration: The University of Washington IRB deemed that recruitment of dog owners for the Dog Aging Project and the administration and content of the DAP surveys are human subjects research that qualifies for category 2 exempt status (IRB ID no. 5988, effective 10/30/2018). All study-related procedures involving privately owned dogs were approved by the Texas A&M University IACUC, under animal use protocols 2021-0317 CAM (effective 12/8/2021 to present) and 2018-0368 CA (effective 12/19/2018 to 12/18/2021). Conflict of interest: The authors declare the following conflicts of interest: MK is a scientific advisor for TriviumVet; DELP is a consultant for WndrHLTH. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Figures

References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical